- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-373/24: Order of the General Court of 7 May 2025 – D&A Pharma v EMA (Action for annulment – Medicinal products for human use – Marketing authorisation for Alcover granules – Unfavourable scientific opinion of the Committee for Medicinal Products for Human Use – Refusal of a request for retraction – No interest in bringing proceedings – Inadmissibility)
ECLI:EU:UNKNOWN:62024TB0373
62024TB0373
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2025/4309
11.8.2025
(Case T-373/24)
(Action for annulment - Medicinal products for human use - Marketing authorisation for Alcover granules - Unfavourable scientific opinion of the Committee for Medicinal Products for Human Use - Refusal of a request for ‘retraction’ - No interest in bringing proceedings - Inadmissibility)
(C/2025/4309)
Language of the case: French
Parties
Applicant: Debrégeas et associés Pharma (D&A Pharma) (Houdan, France) (represented by: N. Viguié, E. Gouesse and V. Durget, lawyers)
Defendant: European Medicines Agency (represented by: S. Drosos, G. Gavriilidou, M. van Egmond and G. Ramo, acting as Agents)
Re:
By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the European Medicines Agency (EMA) of 13 May 2024 by which that agency refused (i) to retract a final opinion of the Committee for Medicinal Products for Human Use of 12 October 2017 concerning the medicinal product Alcover granules, (ii) to provide an update relating to that procedure on the EMA website, and (iii) to publish on that website its correspondence of 30 January and 12 April 2024.
Operative part of the order
The action is dismissed as inadmissible.
Debrégeas et associés Pharma (D&A Pharma) shall pay the costs.
—
(1)
OJ C, C/2024/5426, 16.9.2024.
ELI: http://data.europa.eu/eli/C/2025/4309/oj
ISSN 1977-091X (electronic edition)
—